Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations

Corrado Girmenia, Anna Candoni, Mario Delia, Roberto Latagliata, Alfredo Molteni, Esther N Oliva, Giuseppe A Palumbo, Antonella Poloni, Prassede Salutari, Valeria Santini, Maria Teresa Voso, Pellegrino Musto

Research output: Contribution to journalReview article

Abstract

The improvement in supportive care and the introduction of new therapeutic agents, including lenalidomide and hypomethylating agents, in myelodysplastic syndromes have improved patients' outcomes; however, at the same time, the frequency and epidemiology of infections have changed. Therefore, the great strides in the indications and use of new treatment strategies for myelodysplastic syndromes need a parallel progress in the best approach to prophylaxis and supportive therapy for infections. Based on the recognition that the above issues represent an unmet clinical need in myelodysplastic syndromes, an Italian expert panel performed a review of the literature and composed a framework of the best recommendations for optimal infection control in patient candidates to receive active treatment for myelodysplastic syndromes. In this consensus document we report the outcomes of that review and of the consensus meetings held during 2017. The issues tackled in the project dealt with: information to be collected from candidates for active treatment for myelodysplastic syndromes; how to monitor the risk of infection; antimicrobial prophylaxis; the role of iron chelation and antiviral/antibacterial vaccinations. For each of these issues, practice recommendations are provided.

Original languageEnglish
JournalBlood Reviews
DOIs
Publication statusE-pub ahead of print - Oct 28 2018

Fingerprint

Myelodysplastic Syndromes
Infection Control
Infection
Therapeutics
Antiviral Agents
Vaccination
Epidemiology
Iron

Cite this

Infection control in patients with myelodysplastic syndromes who are candidates for active treatment : Expert panel consensus-based recommendations. / Girmenia, Corrado; Candoni, Anna; Delia, Mario; Latagliata, Roberto; Molteni, Alfredo; Oliva, Esther N; Palumbo, Giuseppe A; Poloni, Antonella; Salutari, Prassede; Santini, Valeria; Voso, Maria Teresa; Musto, Pellegrino.

In: Blood Reviews, 28.10.2018.

Research output: Contribution to journalReview article

Girmenia, Corrado ; Candoni, Anna ; Delia, Mario ; Latagliata, Roberto ; Molteni, Alfredo ; Oliva, Esther N ; Palumbo, Giuseppe A ; Poloni, Antonella ; Salutari, Prassede ; Santini, Valeria ; Voso, Maria Teresa ; Musto, Pellegrino. / Infection control in patients with myelodysplastic syndromes who are candidates for active treatment : Expert panel consensus-based recommendations. In: Blood Reviews. 2018.
@article{ab10919a099c469eae6ed73d10b7831f,
title = "Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations",
abstract = "The improvement in supportive care and the introduction of new therapeutic agents, including lenalidomide and hypomethylating agents, in myelodysplastic syndromes have improved patients' outcomes; however, at the same time, the frequency and epidemiology of infections have changed. Therefore, the great strides in the indications and use of new treatment strategies for myelodysplastic syndromes need a parallel progress in the best approach to prophylaxis and supportive therapy for infections. Based on the recognition that the above issues represent an unmet clinical need in myelodysplastic syndromes, an Italian expert panel performed a review of the literature and composed a framework of the best recommendations for optimal infection control in patient candidates to receive active treatment for myelodysplastic syndromes. In this consensus document we report the outcomes of that review and of the consensus meetings held during 2017. The issues tackled in the project dealt with: information to be collected from candidates for active treatment for myelodysplastic syndromes; how to monitor the risk of infection; antimicrobial prophylaxis; the role of iron chelation and antiviral/antibacterial vaccinations. For each of these issues, practice recommendations are provided.",
author = "Corrado Girmenia and Anna Candoni and Mario Delia and Roberto Latagliata and Alfredo Molteni and Oliva, {Esther N} and Palumbo, {Giuseppe A} and Antonella Poloni and Prassede Salutari and Valeria Santini and Voso, {Maria Teresa} and Pellegrino Musto",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2018",
month = "10",
day = "28",
doi = "10.1016/j.blre.2018.10.002",
language = "English",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Infection control in patients with myelodysplastic syndromes who are candidates for active treatment

T2 - Expert panel consensus-based recommendations

AU - Girmenia, Corrado

AU - Candoni, Anna

AU - Delia, Mario

AU - Latagliata, Roberto

AU - Molteni, Alfredo

AU - Oliva, Esther N

AU - Palumbo, Giuseppe A

AU - Poloni, Antonella

AU - Salutari, Prassede

AU - Santini, Valeria

AU - Voso, Maria Teresa

AU - Musto, Pellegrino

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2018/10/28

Y1 - 2018/10/28

N2 - The improvement in supportive care and the introduction of new therapeutic agents, including lenalidomide and hypomethylating agents, in myelodysplastic syndromes have improved patients' outcomes; however, at the same time, the frequency and epidemiology of infections have changed. Therefore, the great strides in the indications and use of new treatment strategies for myelodysplastic syndromes need a parallel progress in the best approach to prophylaxis and supportive therapy for infections. Based on the recognition that the above issues represent an unmet clinical need in myelodysplastic syndromes, an Italian expert panel performed a review of the literature and composed a framework of the best recommendations for optimal infection control in patient candidates to receive active treatment for myelodysplastic syndromes. In this consensus document we report the outcomes of that review and of the consensus meetings held during 2017. The issues tackled in the project dealt with: information to be collected from candidates for active treatment for myelodysplastic syndromes; how to monitor the risk of infection; antimicrobial prophylaxis; the role of iron chelation and antiviral/antibacterial vaccinations. For each of these issues, practice recommendations are provided.

AB - The improvement in supportive care and the introduction of new therapeutic agents, including lenalidomide and hypomethylating agents, in myelodysplastic syndromes have improved patients' outcomes; however, at the same time, the frequency and epidemiology of infections have changed. Therefore, the great strides in the indications and use of new treatment strategies for myelodysplastic syndromes need a parallel progress in the best approach to prophylaxis and supportive therapy for infections. Based on the recognition that the above issues represent an unmet clinical need in myelodysplastic syndromes, an Italian expert panel performed a review of the literature and composed a framework of the best recommendations for optimal infection control in patient candidates to receive active treatment for myelodysplastic syndromes. In this consensus document we report the outcomes of that review and of the consensus meetings held during 2017. The issues tackled in the project dealt with: information to be collected from candidates for active treatment for myelodysplastic syndromes; how to monitor the risk of infection; antimicrobial prophylaxis; the role of iron chelation and antiviral/antibacterial vaccinations. For each of these issues, practice recommendations are provided.

U2 - 10.1016/j.blre.2018.10.002

DO - 10.1016/j.blre.2018.10.002

M3 - Review article

C2 - 30448050

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

ER -